STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
175
13F, latest reported quarter
What the filings say about OMCL
Insiders, 180 days
-$934.3K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$113.6K
1 notice
Omnicell insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, OMNICELL, INC. insiders sold a net $934.3K of stock across 84 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 2.0% of the 154,785 shares held after it.
1 other insider sold within 30 days.
175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Operating Officer Njoku Nnamdi sold about $133.5K of OMCL on May 18, 2026; 1 other insider sold within 30 days and 175 funds added in the latest 13F quarter.
7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 16, 2026.
The trade is 4.5% of the 112,783 shares held after it.
1 other insider sold within 30 days.
175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J sold about $217.2K of OMCL on May 18, 2026; 1 other insider sold within 30 days and 175 funds added in the latest 13F quarter.
Nobody has filed for crossing 5%. That is a fact, not missing data.
OMCL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Njoku Nnamdi
Filed 2026-08-17
$113.6K
Randall Lipps
Filed 2026-07-15
$470.0K
OMCL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Avory Foundational ETF
$3.5M position · as of 2026-05-29
6.0%
Miller Convertible Total Return ETF
$354.8K position · as of 2026-07-31
2.5%
CRM SMALL CAP VALUE FUND
$1.4M position · as of 2026-07-31
1.9%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.7M position · as of 2026-06-30
1.8%
Global X HealthTech ETF
$397.2K position · as of 2026-05-31
1.6%
Advent Convertible Bond ETF
$501.1K position · as of 2026-05-31
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Veterans Affairs
OMNICELL POU CABINETS AND SERVICES NAC FSS BPA FOR VISN 20 · 2025-10-28
$5.0M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Mr. Lipps
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$11.0M
$4.3M
$3.0M
-54%
-13%
2022
$7.9M
-$13.3M
$2.4M
-38%
-14%
2021
$8.4M
$23.0M
$3.4M
+121%
+14%
2020
$8.0M
$15.5M
$2.3M
+47%
+27%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $934.3K sold by insiders over 180 days, 175 funds added last quarter, $113.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM OMCL
FY Dec 2025
$1.2B
FY Dec 2024
$1.1B
FY Dec 2023
$1.1B
FY Dec 2022
$1.3B
FY Dec 2021
$1.1B
Jun 2026
$312.2M
Mar 2026
$309.9M
Dec 2025
$314.0M
Sep 2025
$310.6M
Jun 2025
$290.6M
Mar 2025
$269.7M
Dec 2024
$306.9M
Sep 2024
$282.4M
At each fiscal year end
Single quarter
Net margin, TTM
+3.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM OMCL
FY Dec 2025
+0.2%
FY Dec 2024
+1.1%
FY Dec 2023
-1.8%
FY Dec 2022
+0.4%
FY Dec 2021
+6.9%
Jun 2026
+7.8%
Mar 2026
+3.7%
Dec 2025
-0.6%
Sep 2025
+1.8%
Jun 2025
+1.9%
Mar 2025
-2.6%
Dec 2024
+5.2%
Sep 2024
+3.1%
At each fiscal year end
Single quarter
Free cash flow, TTM
$142.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM OMCL
FY Dec 2025
$86.9M
FY Dec 2024
$151.3M
FY Dec 2023
$139.6M
FY Dec 2022
$30.2M
FY Dec 2021
$202.8M
Jun 2026
$59.4M
Mar 2026
$42.1M
Dec 2025
$22.6M
Sep 2025
$18.5M
Jun 2025
$31.0M
Mar 2025
$14.8M
Dec 2024
$47.2M
Sep 2024
$13.9M
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2020-06-30 (73 months older than the period end) plus current 2018-12-31 (91 months older than the period end); equity 2026-06-30
Debt to equity OMCL
FY Dec 2025
0.00x
FY Dec 2024
0.00x
FY Dec 2023
0.00x
FY Dec 2022
0.00x
FY Dec 2021
0.00x
Jun 2026
0.00x
Mar 2026
0.00x
Dec 2025
0.00x
Sep 2025
0.00x
Jun 2025
0.00x
Mar 2025
0.00x
Dec 2024
0.00x
Sep 2024
0.00x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt OMCL
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+3.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity OMCL
FY Dec 2025
+0.2%
FY Dec 2024
+1.0%
FY Dec 2023
-1.8%
FY Dec 2022
+0.5%
FY Dec 2021
+7.4%
Jun 2026
+3.1%
Mar 2026
+1.6%
Dec 2025
+0.2%
Sep 2025
+1.6%
Jun 2025
+1.9%
Mar 2025
+1.7%
Dec 2024
+1.0%
Sep 2024
-1.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets OMCL
FY Dec 2025
+0.1%
FY Dec 2024
+0.6%
FY Dec 2023
-0.9%
FY Dec 2022
+0.3%
FY Dec 2021
+3.9%
Jun 2026
+1.9%
Mar 2026
+1.0%
Dec 2025
+0.1%
Sep 2025
+0.9%
Jun 2025
+1.0%
Mar 2025
+1.0%
Dec 2024
+0.6%
Sep 2024
-0.8%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+4.0%
operating income after a 36.1% effective tax rate, over long-term 2020-06-30 (73 months older than the period end) plus current 2018-12-31 (91 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital OMCL
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
+4.0%
Mar 2026
+1.9%
Dec 2025
n/a
Sep 2025
+1.2%
Jun 2025
+1.3%
Mar 2025
+0.9%
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+3.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed OMCL
FY Dec 2025
+0.3%
FY Dec 2024
+0.0%
FY Dec 2023
-1.9%
FY Dec 2022
-0.2%
FY Dec 2021
+6.4%
Jun 2026
+3.7%
Mar 2026
+2.2%
Dec 2025
+0.3%
Sep 2025
+1.2%
Jun 2025
+0.9%
Mar 2025
+0.6%
Dec 2024
+0.0%
Sep 2024
-2.2%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
44.01x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing OMCL
FY Dec 2025
1,132.50x
FY Dec 2024
164.89x
FY Dec 2023
n/a
FY Dec 2022
387.85x
FY Dec 2021
112.07x
Jun 2026
49.43x
Mar 2026
75.86x
Dec 2025
1,132.50x
Sep 2025
70.81x
Jun 2025
58.80x
Mar 2025
76.00x
Dec 2024
164.89x
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.4B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2020-06-30 (73 months older than the period end) plus current 2018-12-31 (91 months older than the period end), minus cash 2026-06-30
Enterprise value OMCL
FY Dec 2025
$1.8B
FY Dec 2024
$1.7B
FY Dec 2023
$1.2B
FY Dec 2022
$1.9B
FY Dec 2021
$7.6B
Jun 2026
$1.6B
Mar 2026
$1.3B
Dec 2025
$1.8B
Sep 2025
$1.2B
Jun 2025
$978.2M
Mar 2025
$1.2B
Dec 2024
$1.7B
Sep 2024
$1.4B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+8.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield OMCL
FY Dec 2025
+4.3%
FY Dec 2024
+7.3%
FY Dec 2023
+8.2%
FY Dec 2022
+1.3%
FY Dec 2021
+2.6%
Jun 2026
+7.6%
Mar 2026
+7.5%
Dec 2025
+4.3%
Sep 2025
+8.0%
Jun 2025
+7.8%
Mar 2025
+7.6%
Dec 2024
+7.3%
Sep 2024
+6.7%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.65x
P/E over trailing EPS growth of 68%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing OMCL
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
0.95x
Jun 2026
0.73x
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
OMCL ranks highest on financial health (99th percentile) and institutional and government (43rd), and lowest on insider conviction (26th), among Tech Hardware peers.
Profitability
40
Inputs
Return on equity+3.1% · 49 pct, sector of 77
Return on assets+1.9% · 54 pct, sector of 92
Return on invested capital+4.0% · 10 pct, universe of 1,069
Return on capital employed+3.7% · 48 pct, sector of 72
Financial health
100
Inputs
Debt to equity0.00x · 100 pct, sector of 72
Cash flow to debtno debt to cover
Growth
36
Inputs
Revenue growth, YoY+6.5% · 43 pct, sector of 102
Backlog growth, YoY-2.3% · 30 pct, sector of 48
Insider conviction
26
Inputs
Net Form 4 buying (codes P and S), 180d-$934K · 51 pct, sector of 75
Insider buyers, 180d0 · 0 pct, sector of 77
Institutional and government
43
Inputs
Funds adding, latest quarter175 · 68 pct, sector of 89
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quarters$100K · 17 pct, universe of 1,063
Risk and compliance
33
Inputs
Short interest, % of float+8.2% · 35 pct, sector of 105
Recalls per $1B revenue, 3y1.69 per $1B · 20 pct, universe of 292
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+14.2% · 46 pct, sector of 80
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OMCL filings, in plain words
Are Omnicell insiders buying or selling OMCL?
In the 180 days to 2026-10-28, Omnicell insiders were net sellers, a net $934.3K across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of OMCL?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $113.6K of stock; the latest, by Njoku Nnamdi, was filed 2026-08-17.
Read the full summary
In the 180 days to 2026-10-28, Omnicell insiders were net sellers of OMCL, a net $934.3K across purchases and sales reported on Form 4 by 3 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $113.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.